P110008/S015: coflex Interlaminar Technology
FDA’s recorded scope: The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) supplement, which requested termination of study enrollment and subject follow-up for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P110008. Based upon the information submitted, the PMA supplement is approved.
